Resistance Patterns in HIV-2 Treatment: A Case Report
Author Information
Author(s): van Kampen Jeroen J A, van Nood Els, Mahmud Rizwan, Krullaars Zoë, Voskamp Tess, Voskamp Mike, Nijssen Tess, Voermans Jolanda J C, Charpentier Charlotte, Le Hingrat Quentin, van de Vijver David, Gruters Rob A, Mesplède Thibault
Primary Institution: Erasmus MC, Rotterdam, The Netherlands
Hypothesis
What are the resistance patterns of HIV-2 to dolutegravir and lenacapavir?
Conclusion
Lenacapavir shows potential in HIV-2 treatment but must be combined with other effective antiretroviral agents to prevent resistance.
Supporting Evidence
- Lenacapavir was added to a failing regimen and initially reduced viral load.
- Resistance mutations were identified during treatment.
- The patient experienced a rebound in viral load after initial improvement.
Takeaway
This study is about a person with HIV-2 who had trouble getting better with certain medicines, but a new medicine called lenacapavir helped a little when used with other drugs.
Methodology
The case involved clinical monitoring, genotypic and phenotypic resistance assays, and in silico structural modeling.
Potential Biases
Potential conflicts of interest were reported, including funding from pharmaceutical companies.
Limitations
The study is based on a single case, which may not represent broader populations.
Participant Demographics
An adult female diagnosed with HIV-2 in 2002.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website